The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcutaneously can protect children from P. falciparum infection in a region where this organism is endemic is unclear. ⋯ Subcutaneous administration of L9LS to children was protective against P. falciparum infection and clinical malaria over a period of 6 months. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT05304611.).
-
Comment Letter Randomized Controlled Trial
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura.
Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived products) administered as routine prophylaxis or on-demand treatment in patients with congenital TTP is not known. ⋯ During prophylaxis with recombinant ADAMTS13 in patients with congenital TTP, ADAMTS13 activity reached approximately 100% of normal levels, adverse events were generally mild or moderate in severity, and TTP events and manifestations were rare. (Funded by Takeda Development Center Americas and Baxalta Innovations; ClinicalTrials.gov number, NCT03393975.).